Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P10415 (
Bcl-2
)
33,771
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The
NPM-MLF1
chimeric protein is produced by the t(3;5)(q25.1;q34) chromosomal translocation, which is associated with myelodysplastic syndrome (MDS) prior to progression into acute myeloid leukemia (AML). Here we report that K562 human leukemia cells ectopically expressing
NPM-MLF1
, but not those with wild-type MLF1, were gradually eliminated from the culture by undergoing apoptosis. NIH3T3 mouse fibroblasts engineered to overexpress
NPM-MLF1
grew normally but serum deprivation triggered apoptotic cell death with slower kinetics than did other well-known apoptotic inducers such as c-Myc or E2F-1. Quantitative analysis of apoptotic induction confirmed that, neither NPM nor MLF1, but the
NPM-MLF1
fusion protein was able to induce apoptosis. Analyses using a variety of deletion mutants of
NPM-MLF1
revealed that induction of apoptosis required the N-terminal domain of MLF1 and the NPM domain containing nuclear localization signal and that removal of the NPM dimerization domain markedly impaired the ability to induce apoptosis. Co-expression of
Bcl-2
rescued NIH3T3 fibroblasts from
NPM-MLF1
-mediated cell death without affecting the expression level or the subcellular localization of
NPM-MLF1
and enabled cells to progress into S phase in low serum. These findings provide an
NPM-MLF1
-mediated novel mechanism of apoptotic induction and imply that NPM-MLFI in collaboration with anti-apoptotic oncoproteins may play an important role in multi-step progression from MDS to AML.
...
PMID:Apoptosis induced by the myelodysplastic syndrome-associated NPM-MLF1 chimeric protein. 1039 79
Myeloid leukemia factor 1
(
MLF1
) was involved in t(3;5) chromosomal rearrangement and aberrantly expressed in myelodysplastic syndromes/acute myeloid leukemia patients. Ex vivo experiments showed that the lymphocytes from the Mlf1-deficient mice were more resistant to apoptotic stimulations than the wild-type cells. Furthermore, the ectopically expressed
MLF1
induced apoptosis in the cell models. These findings revealed that
MLF1
was required for the cells to respond to the apoptotic stimulations. Ex vivo experiments also demonstrated that cytokine withdrawal significantly up-regulated Mlf1's expression and promoted its association with B cell lymphoma-extra large (Bcl-XL) in the lymphocytes, at the same time reduced the association of Bax with Bcl-XL The same effects were also observed in the cells that over-expressed
MLF1
. However, these effects were observed in Mlf1 null lymphocytes as well as the cells over-expressing Bcl-XL. In addition,
MLF1
's proapoptosis could be completely prevented by co-expression of Bcl-XL and significantly attenuated in Bax/Bak double null cells. These data, taken together, strongly suggested that in response to the stresses, up-regulated Mlf1 promoted its association with Bcl-XL and reduced the available Bcl-XL for associating with Bax, which resulted in releasing Bax from the Bcl-XL and apoptosis in turn. Lastly, we showed that
MLF1
was negatively regulated by 14-3-3 and revealed that 14-3-3 bound to
MLF1
and physically blocked
MLF1
's
Bcl-2
homology domain 3 (BH3) as well as Bcl-XL from associating with
MLF1
. Our findings suggested that ectopically expressed
MLF1
could be responsible for the pathological apoptosis in early myelodysplastic syndrome (MDS) patients.
...
PMID:Myeloid leukemia factor 1 interfered with Bcl-XL to promote apoptosis and its function was regulated by 14-3-3. 2656 51